Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Biosplice Therapeutics, Inc. clinical trials
Also known as Samumed.
The registry lists 22 studies whose lead sponsor is Biosplice Therapeutics, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 21, 2026.
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Biosplice Therapeutics, Inc..
- Biosplice Therapeutics, Inc.22 studiesSame company
Something wrong?
Focus areas
Conditions Biosplice Therapeutics, Inc. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 22 of 22.
- A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)CompletedNCT02275351Phase 2
- A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic AlopeciaCompletedNCT03742518Phase 2/3
- A Repeat Insult Patch Test (RIPT) Study Evaluating the Sensitization Potential of Topical SM04755 Solution in Healthy VolunteersCompletedNCT03502434Phase 1
- A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post DosingCompletedNCT02503137Phase 2
- Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic CancerCompletedNCT02191761Phase 1
- Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Knee Osteoarthritis (STRIDES)CompletedNCT05603754Phase 3
- 3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee OsteoarthritisTerminatedNCT04931667Phase 3
- A Long-Term Safety and Efficacy Study of Lorecivivint in Subjects With Osteoarthritis of the KneeTerminatedNCT04520607Phase 3
- MRI Study to Evaluate the Safety and Efficacy of SM04690 for Knee OsteoarthritisTerminatedNCT03706521Phase 2
- Patient-Reported and Radiographic Outcomes in Evaluating Lorecivivint (SM04690) for the Treatment of Knee OsteoarthritisCompletedNCT03928184Phase 3
- Patient-Reported Outcomes in Evaluating Lorecivivint (SM04690) for Moderate to Severe Knee Osteoarthritis (STRIDES-1)CompletedNCT04385303Phase 3
- Safety and Bone Health Study of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee OsteoarthritisCompletedNCT03727022Phase 2
- A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid TumorsTerminatedNCT03355066Phase 1
- A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid TumorsTerminatedNCT05084859Phase 1
- A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee OsteoarthritisCompletedNCT03122860Phase 2
- A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis SubjectsCompletedNCT02536833Phase 2
- Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy VolunteersCompletedNCT04598542Phase 1
- An Observational Study Evaluating the Safety, Tolerability, and Efficacy of Treatment of SM04690 or Placebo Previously Injected in the Target Knee Joint of Subjects With Moderately to Severely Symptomatic OsteoarthritisCompletedNCT02951026
- A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc DiseaseTerminatedNCT03246399Phase 1
- A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SM04646 Inhalation Solution in Subjects With Idiopathic Pulmonary Fibrosis (IPF)WithdrawnNCT03591926Phase 2
- A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SM04755 Following Topical Administration to Healthy SubjectsCompletedNCT03229291Phase 1
- Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA)CompletedNCT02095548Phase 1